Physician profile
Minna Cheng
NPI 1144752080
$3,483.16
in general payments reported to CMS, 2019-2025
23 companies · $642 in 2025
The $642 reported for 2025 was more than what 96% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $16.03 · 2021: $402 · 2022: $693 · 2023: $829 · 2024: $901 · 2025: $642.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,372.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,371.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rhythm Pharmaceuticals, INC. | $926.16 | 2021-2025 | Imcivree, Imcivree |
| Sanofi-Aventis U.S. LLC | $311.23 | 2024-2025 | |
| Ascendis Pharma Endocrinology INC | $293.61 | 2022-2025 | Skytrofa |
| Tolmar Pharmaceuticals, INC. | $265.49 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $246.21 | 2021-2025 | Vaxneuvance, Gardasil 9, Vaxelis |
| Novo Nordisk INC | $223.65 | 2021-2025 | Sogroya, Wegovy |
| Abbvie INC. | $206.34 | 2021-2025 | Lupron Depot |
| Cranial Technologies, INC | $193.12 | 2020-2025 | Doc Band |
| Tolmar, INC. | $123.09 | 2023-2025 | Fensolvi |
| Sobi, INC | $93.01 | 2021-2024 | |
| Glaxosmithkline, LLC. | $91.89 | 2023-2025 | Bexsero |
| Biomarin Pharmaceutical INC. | $89.64 | 2024 | Voxzogo 1.2mg |
| Alexion Pharmaceuticals, INC. | $82.96 | 2021-2024 | Strensiq |
| Phadia US INC. | $72.90 | 2023-2025 | Immunocap |
| Pfizer INC. | $54.12 | 2023-2024 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $53.16 | 2022-2023 | |
| Kyowa Kirin, INC. | $42.74 | 2023 | Crysvita |
| Ultragenyx Pharmaceutical INC. | $33.81 | 2022-2023 | |
| Medtronic, INC. | $18.52 | 2022 | |
| Azurity Pharmaceuticals, INC. | $16.28 | 2022 | |
| Xeris Pharmaceuticals, INC. | $16.16 | 2022 | |
| Eton Pharmaceuticals, INC. | $15.08 | 2023 | Alkindi |
| Abbott Laboratories | $13.99 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Minna Cheng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.